Research News

Research News Image

Genetic Testing Shows Promise for Medication Selection for MDD

Jul 12 2022
Antidepressants are often one of the first treatment approaches for individuals with depressive disorders, but many struggle with side effects and finding the appropriate medication or dosage. Recent findings from a randomized controlled trial indicate that pharmacogenomic testing could be helpful in medication selection for patients with major depressive disorder (MDD). Participants who were prescribed medication and dosage based on their genetic testing results were less likely to present drug-gene interactions and more likely to experience remission over 24 weeks. However, the researchers note that the participants' improvements are not significant compared to the control group at the the 24-week mark. Pharmacogenic testing is an evolving field, and more research is needed to fully understand its efficacy for individuals with mental health conditions. To learn more, see the study in JAMA.